JP Morgan Chase’s XBiotech XBIT Stock Holding History

JP Morgan Chase’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,000	Closed	-$197K	–	5657
2017 Q4	$197K	Buy	+50,000	New	+$210K	﹤0.01%	4420

Other funds holding XBIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase's XBIT Position: Q2 2026 in Review

JP Morgan Chase held its XBiotech (XBIT) position steady in Q2 2026 at 96 shares worth $224. The position accounts for ﹤0.01% of the portfolio, ranked #7492.

JP Morgan Chase first reported a position in XBIT in Q2 2016 and has held it in 35 quarters since. The position peaked at $438K in Q1 2021. 36 funds tracked by Wall St. Rank hold XBIT as of Q2 2026.

JP Morgan Chase held 96 shares of XBiotech worth $224 as of Q2 2026.
JP Morgan Chase left its XBiotech share count unchanged in Q2 2026.
XBiotech made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7492 holding.
JP Morgan Chase first reported a position in XBiotech in Q2 2016 and has held it in 35 quarters since.
JP Morgan Chase's XBiotech position peaked at $438K in Q1 2021.
36 funds tracked by Wall St. Rank held XBiotech as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.